Although tocilizumab administration in COVID-19 is hypothesised that modulating IL-6 levels may reduce the duration or/and severity of COVID-19, suppression of the host immune response is considered a possible disadvantage of using this agent [9]. Here, IL6 is linked to COVID-19.